Incidence, evolution and risk factors of hypophosphatemia in patients with solid tumors receiving ferric carboxymaltose: a retrospective cohort study

References

• Cella D, Kallich J, McDermott A, et al. The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann Oncol. 2004;15(6):979–986.
   PubMed Web of Science ®Google Scholar
• Ludwig H, Muldur E, Endler G, et al. Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia. Ann Oncol. 2013;24(7):1886–1892.
   PubMed Web of Science ®Google Scholar
• Dicato M, Plawny L, Diederich M. Anemia in cancer. Ann Oncol. 2010;21(7):vii167–72.
   PubMed Web of Science ®Google Scholar
• Aapro M, Osterborg A, Gascon P, et al. Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron. Ann Oncol. 2012;23(8):1954–1962.
   PubMed Web of Science ®Google Scholar
• Bohlius J, Bohlke K, Castelli R, et al. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. J Clin Oncol. 2019;37(15):1336–1351.
   PubMed Web of Science ®Google Scholar
• Aapro M, Beguin Y, Bokemeyer C, et al. Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2018;29(Suppl 4):iv96–iv110.
   PubMedGoogle Scholar
• Mhaskar R, Wao H, Miladinovic B, et al. The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents. Cochrane Database Syst Rev. 2016;2(2):CD009624.
   PubMedGoogle Scholar
• EMA CHMP. Assessment report for: iron containing intravenous (IV) medicinal products EMA/549569/2013. 2013. [cited 2022 Jan 19]. Available from: https://www.ema.europa.eu/en/documents/referral/intravenous-iron-containing-medicinal-products-article-31-referral-assessment-report_en.pdf
   Google Scholar
• Bailie GR, Horl WH, Verhoef JJ. Differences in spontaneously reported hypersensitivity and serious adverse events for intravenous iron preparations: comparison of Europe and North America. Arzneimittelforschung. 2011;61(5):267–275.
   PubMed Web of Science ®Google Scholar
• Pharma UK Ltd V. Ferinject® (ferric carboxymaltose): summary of product characteristics. [cited 2022 Jan 19]. Available from: https://www.medicines.org.uk/emc/product/5910/
   Google Scholar
• Pharmacosmos UK Ltd. Monofer® (ferric derisomaltose): summary of product characteristics. [cited 2022 Jan 19]. Available from: https://www.medicines.org.uk/emc/product/5676/
   Google Scholar
• American Regent, Inc. Injectafer® (ferric carboxymaltose): package insert. [cited 2022 Jan 19] Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/203565s014lbl.pdf
   Google Scholar
• Schaefer B, Tobiasch M, Viveiros A, et al. Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside—a systematic review and meta-analysis. Br J Clin Pharmacol. 2021;87(5):2256–2273.
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K, Ganz T, Trumbo H, et al. Parenteral iron therapy and phosphorus homeostasis: a review. Am J Hematol. 2021;96(5):606–616.
   PubMed Web of Science ®Google Scholar
• Schaefer B, Tobiasch M, Wagner S, et al. Hypophosphatemia after intravenous iron therapy: comprehensive review of clinical findings and recommendations for management. Bone. 2022;154:116202.
   PubMed Web of Science ®Google Scholar
• Glaspy JA, Wolf M, Strauss WE. Intravenous iron-induced hypophosphatemia: an emerging syndrome. Adv Ther. 2021;38(7):3531–3549.
   PubMed Web of Science ®Google Scholar
• Rosano G, Schiefke I, Gohring UM, et al. A pooled analysis of serum phosphate measurements and potential hypophosphataemia events in 45 interventional trials with ferric carboxymaltose. J Clin Med. 2020;9(11):3587.
   PubMed Web of Science ®Google Scholar
• Vilaca T, Velmurugan N, Smith C, et al. Osteomalacia as a complication of intravenous iron infusion: a systematic review of case reports. J Bone Miner Res. 2022;37(6):1188–1199.
   PubMed Web of Science ®Google Scholar
• Schaefer B, Zoller H, Wolf M. Risk factors for and effects of persistent and severe hypophosphatemia following ferric carboxymaltose. J Clin Endocrinol Metab. 2021.
   Web of Science ®Google Scholar
• Adhikari S, Mamlouk O, Rondon-Berrios H, et al. Hypophosphatemia in cancer patients. Clin Kidney J. 2021;14(11):2304–2315.
   PubMed Web of Science ®Google Scholar
• Cederholm T, Jensen GL, Correia M, et al. GLIM criteria for the diagnosis of malnutrition - A consensus report from the global clinical nutrition community. Clin Nutr. 2019;38(1):1–9.
   PubMed Web of Science ®Google Scholar
• McMillan DC. The systemic inflammation-based Glasgow prognostic score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39(5):534–540.
   PubMed Web of Science ®Google Scholar
• Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–612.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Common terminology criteria for adverse events (CTCAE). [cited 2022 Jan 21]. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm
   Google Scholar
• Gelman A, Hill J. Data analysis using regression and hierarchical/multilevel models. New York: Cambridge University Press; 2007.
   Google Scholar
• Asanjarani A, Liquet B, Nazarathy Y. Estimation of semi-Markov multi-state models: a comparison of the sojourn times and transition intensities approaches. Int J Biostat. 2021.
   PubMedGoogle Scholar
• Amorim LD, Cai J. Modelling recurrent events: a tutorial for analysis in epidemiology. Int J Epidemiol. 2015;44(1):324–333.
   PubMed Web of Science ®Google Scholar
• Gran JM, Lie SA, Oyeflaten I, et al. Causal inference in multi-state models-sickness absence and work for 1145 participants after work rehabilitation. BMC Public Health. 2015;15(1):1082.
   PubMedGoogle Scholar
• Breskin A, Edmonds A, Cole SR, et al. G-computation for policy-relevant effects of interventions on time-to-event outcomes. Int J Epidemiol. 2020;49(6):2021–2029.
   Web of Science ®Google Scholar
• R Core Team. R: a language and environment for statistical computing. Vienna: Austria; 2016. Available from: https://www.R-project.org/.
   Google Scholar
• Steinmetz T, Tschechne B, Harlin O, et al. Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. Ann Oncol. 2013;24(2):475–482.
   PubMed Web of Science ®Google Scholar
• Toledano A, Luporsi E, Morere JF, et al. Clinical use of ferric carboxymaltose in patients with solid tumours or haematological malignancies in France. Support Care Cancer. 2016;24(1):67–75.
   PubMed Web of Science ®Google Scholar
• Makharadze T, Boccia R, Krupa A, et al. Efficacy and safety of ferric carboxymaltose infusion in reducing anemia in patients receiving chemotherapy for nonmyeloid malignancies: a randomized, placebo-controlled study (IRON-CLAD). Am J Hematol. 2021;96(12):1639–1646.
   PubMed Web of Science ®Google Scholar
• Abdel-Razeq H, Saadeh SS, Malhis R, et al. Treatment of anemia in cancer patients undergoing chemotherapy with intravenous ferric carboxymaltose without erythropoiesis-stimulating agents. Ther Adv Med Oncol. 2020;12:1758835920953292.
   Web of Science ®Google Scholar
• Kim YW, Bae JM, Park YK, et al. Effect of intravenous ferric carboxymaltose on hemoglobin response among patients with acute isovolemic anemia following gastrectomy: the FAIRY randomized clinical trial. JAMA. 2017;317(20):2097–2104.
   PubMed Web of Science ®Google Scholar
• Calleja JL, Delgado S, Del Val A, et al. Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia. Int J Colorectal Dis. 2016;31(3):543–551.
   PubMed Web of Science ®Google Scholar
• Laso-Morales MJ, Vives R, Bisbe E, et al. Single-dose intravenous ferric carboxymaltose infusion versus multiple fractionated doses of intravenous iron sucrose in the treatment of post-operative anaemia in colorectal cancer patients: a randomised controlled trial. Blood Transfus. 2021;20(4):310–318.
   PubMed Web of Science ®Google Scholar
• Keeler BD, Simpson JA, Ng O, et al. Randomized clinical trial of preoperative oral versus intravenous iron in anaemic patients with colorectal cancer. Br J Surg. 2017;104(3):214–221.
   PubMed Web of Science ®Google Scholar
• Borstlap WAA, Buskens CJ, Tytgat K, et al. Multicentre randomized controlled trial comparing ferric(III)carboxymaltose infusion with oral iron supplementation in the treatment of preoperative anaemia in colorectal cancer patients. BMC Surg. 2015;15(1):78.
   PubMedGoogle Scholar
• Marinho J, Leao I, Custodio S, et al. Ferric Carboxymaltose in the treatment of chemotherapy-induced anaemia: an effective, safe and cost- sparing alternative to blood transfusion. Sci Rep. 2019;9(1):20410.
   PubMedGoogle Scholar
• Jang JH, Kim Y, Park S, et al. Efficacy of intravenous iron treatment for chemotherapy-induced anemia: a prospective Phase II pilot clinical trial in South Korea. PLoS Med. 2020;17(6):e1003091.
   PubMed Web of Science ®Google Scholar
• Lima J, Gago P, Rocha M, et al. Role of intravenous iron in the treatment of anemia in patients with gastrointestinal tract tumors undergoing chemotherapy: a single-center, observational study. Int J Gen Med. 2018;11:331–336.
   PubMed Web of Science ®Google Scholar
• Coussirou J, Debourdeau A, Stancu A, et al. Impact of ferric carboxymaltose on the evolution of hemoglobin and ECOG performance status in iron-deficient patients with solid tumors: a 3-month follow-up retrospective study. Support Care Cancer. 2018;26(11):3827–3834.
   PubMed Web of Science ®Google Scholar
• Verhaeghe L, Bruyneel L, Stragier E, et al. The effectiveness of intravenous iron for iron deficiency anemia in gastrointestinal cancer patients: a retrospective study. Ann Gastroenterol. 2017;30(6):654–663.
   PubMed Web of Science ®Google Scholar
• Wolf M, Chertow GM, Macdougall IC, et al. Randomized trial of intravenous iron-induced hypophosphatemia. JCI Insight. 2018;3(23). DOI:10.1172/jci.insight.124486.
   Web of Science ®Google Scholar
• Haneuse S, Rotnitzky A. Estimation of the effect of interventions that modify the received treatment. Stat Med. 2013;32(30):5260–5277.
   PubMed Web of Science ®Google Scholar